Bayer to Present New Clinical Data in Indolent non-Hodgkin's Lymphoma and Additional Research on its Oncology Portfolio at AACR Annual Meeting 2021

Published Apr 06 2021 at 4:31 PM GMT
  • Oral presentation in Clinical Trials Plenary Session on April 10 to highlight the Phase III trial CHRONOS-3 evaluating the investigational combination of Aliqopa® (copanlisib) plus rituximab compared to rituximab and placebo in relapsed indolent non-Hodgkin's Lymphoma (iNHL) New data also include research into Bayer's biomarker-driven treatment Vitrakvi® (larotrectinib) on long-term outcomes in patients with TRK fusion cancer and biomarker research in this patient population Data from NUBEQA® (darolutamide), Xofigo® (radium Ra 223 dichloride), and targeted thorium conjugates (TTC) from Bayer's Targeted Alpha Therapy platform will be showcased Introduction of investigational treatment approaches in the areas of precision molecular oncology and immuno-oncology" Abstracts: CT001, CT020, 394, 1008, 1392, 1393, 1470, 1722 Bayer will present new research across its oncology portfolio at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021, taking place over two weeks on April 10-15 and May 17-21, 2021.
  • The data include an oral presentation in a Clinical Trials Plenary Session on the Phase III randomized, double-blind, placebo-controlled clinical study of the investigational use of Aliqopa® (copanlisib) in combination with rituximab given intravenously in patients with relapsed indolent non-Hodgkin's Lymphoma (iNHL) who have relapsed after "1 line of treatment, including rituximab (CHRONOS-3).
  • In 2017, Aliqopa was approved for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies based on the results of a single arm, multi-center, Phase II clinical trial (CHRONOS-1).1 Accelerated approval was granted for this indication based on overall response rate (ORR).
  • Continued approval for this indication is contingent upon verification and description of clinical benefit in a confirmatory trial.
  • Data related to Bayer's biomarker-driven treatment Vitrakvi® (larotrectinib), a first-in-class TRK inhibitor for TRK fusion cancer across.


  • Published Apr 6, 2021 4:31 PM GMT